CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 5 enrolled
Drug / intervention
CS-101biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06024876
NCT06024876Early Ph 1Completed
CompareCT.gov

A Clinical Study Evaluating the Safety and Efficacy of Ex-vivo tBE Edited Autologous Hematopoietic Stem Progenitor Cells (CS-101) in Treating Subjects With β-thalassemia

CorrectSequence Therapeutics Co., Ltd·interventional·Posted Sep 6, 2023·Updated Feb 12, 2026

In Brief

A Early Phase 1 clinical trial evaluating CS-101 for Beta-Thalassemia. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating β-thalassemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBeta-Thalassemia
CountriesChina
CollaboratorsFirst Affiliated Hospital of Guangxi Medical University

Timeline

Early Ph 1CompletedFinished
202420252026
First PostedSep 6, 2023
Enrollment StartAug 26, 2023
Primary CompletionJul 1, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 2.8 years ago

Interventions

CS-101biological

Autologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique